<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Picard Medical, Inc. — News on 6ix</title>
<link>https://6ix.com/company/picard-medical-inc</link>
<description>Latest news and press releases for Picard Medical, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 05 May 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/picard-medical-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo695e56ea905484111c2fee40.webp</url>
<title>Picard Medical, Inc.</title>
<link>https://6ix.com/company/picard-medical-inc</link>
</image>
<item>
<title>Picard Medical Announces Pricing of $5 Million Offering</title>
<link>https://6ix.com/company/picard-medical-inc/news/picard-medical-announces-pricing-of-dollar5-million-offering</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/picard-medical-announces-pricing-of-dollar5-million-offering</guid>
<pubDate>Tue, 05 May 2026 12:00:00 GMT</pubDate>
<description>TUCSON, Ariz., May 05, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems, LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced the pricing of its "reasonable best efforts" offering with certain new and existing institutional investors for the purchase and sale of (i) 16,666,667 shares of the Company’s common stock, par value $0.0001 per share (or common stock e</description>
</item>
<item>
<title>Picard Medical / SynCardia Featured in Interview Series with The Mullings Group</title>
<link>https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-featured-in-interview-series-with-the-mullings-group</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-featured-in-interview-series-with-the-mullings-group</guid>
<pubDate>Wed, 29 Apr 2026 12:00:00 GMT</pubDate>
<description>– Discussions to highlight total artificial heart therapy, advanced heart failure market, and next-generation platform development – TUCSON, Ariz., April 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems LLC (“SynCardia”), maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, announced today it has been featured in a two-part interview series with Joe Mulling</description>
</item>
<item>
<title>Picard Medical / SynCardia Reports Revenue Growth Based on Top-line Results for the First Quarter 2026</title>
<link>https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-reports-revenue-growth-based-on-top-line-results-for-the-first-quarter-2026</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-reports-revenue-growth-based-on-top-line-results-for-the-first-quarter-2026</guid>
<pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
<description>– Growth driven by increased U.S. demand and pricing –TUCSON, Ariz., April 22, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC, (“SynCardia”) maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced preliminary, unaudited top-line revenues for the first quarter ended March 31, 2026. Revenue rose 79.9% to $1.1 million for the three months ended</description>
</item>
<item>
<title>Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product</title>
<link>https://6ix.com/company/picard-medical-inc/news/philip-morris-international-announces-us-fda-reauthorization-of-iqos-as-a-modified-risk-tobacco-product-1</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/philip-morris-international-announces-us-fda-reauthorization-of-iqos-as-a-modified-risk-tobacco-product-1</guid>
<pubDate>Fri, 17 Apr 2026 21:43:00 GMT</pubDate>
<description>STAMFORD, CT, April 17, 2026--The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes.</description>
</item>
<item>
<title>Picard Medical / SynCardia to Present Next Generation Total Artificial Heart Platform at ISHLT 2026 in Toronto</title>
<link>https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-to-present-next-generation-total-artificial-heart-platform-at-ishlt-2026-in-toronto</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-to-present-next-generation-total-artificial-heart-platform-at-ishlt-2026-in-toronto</guid>
<pubDate>Thu, 16 Apr 2026 22:56:00 GMT</pubDate>
<description>Picard to showcase the SynCardia TAH and next-generation innovationTUCSON, Ariz., April 16, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC, (“SynCardia”) maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced its participation in the International Society for Heart and Lung Transplantation (“ISHLT”) 2026 Annual Meeting, to be held at the Me</description>
</item>
<item>
<title>Picard Medical / SynCardia Highlights Total Artificial Heart Bridge to Transplant Case at Texas Children's Hospital</title>
<link>https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-highlights-total-artificial-heart-bridge-to-transplant-case-at-texas-childrens-hospital</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-highlights-total-artificial-heart-bridge-to-transplant-case-at-texas-childrens-hospital</guid>
<pubDate>Wed, 15 Apr 2026 12:00:00 GMT</pubDate>
<description>SynCardia Total Artificial Heart supports patient through complex re-transplant journeyTUCSON, Ariz., April 15, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today highlighted the successful use of the SynCardia Total Artificial Heart (“STAH”) as a bridge to heart transplantation at Texas Children’s</description>
</item>
<item>
<title>Philip Morris International Joins Ferrari Hypersail as Principal Partner, Building on 50-Year Relationship</title>
<link>https://6ix.com/company/picard-medical-inc/news/philip-morris-international-joins-ferrari-hypersail-as-principal-partner-building-on-50-year-relationship-1</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/philip-morris-international-joins-ferrari-hypersail-as-principal-partner-building-on-50-year-relationship-1</guid>
<pubDate>Mon, 13 Apr 2026 12:00:00 GMT</pubDate>
<description>STAMFORD, CT, April 13, 2026--Philip Morris International (NYSE: PM) today announced it will serve as Principal Partner of Ferrari Hypersail, an initiative that applies Ferrari engineering and racing spirit to a new frontier at sea. PMI has shared with Ferrari one of the most enduring partnerships in Formula 1 since its origins in 1973 - a relationship defined by reinvention, ambition, and an unwavering belief that progress matters. Philip Morris International’s commitment to science-backed inno</description>
</item>
<item>
<title>Picard Medical / SynCardia COO to Deliver Keynote at Venture Café Phoenix During Arizona Tech Week</title>
<link>https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-coo-to-deliver-keynote-at-venture-cafe-phoenix-during-arizona-tech-week-36</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-coo-to-deliver-keynote-at-venture-cafe-phoenix-during-arizona-tech-week-36</guid>
<pubDate>Thu, 02 Apr 2026 12:00:00 GMT</pubDate>
<description>– Keynote to highlight innovation in artificial heart technology and expanding access for women with advanced heart failure – TUCSON, Ariz., April 02, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Chief Operating Officer Matt Schuster will deliver a keynote address at Venture Café Phoenix during Ariz</description>
</item>
<item>
<title>Picard Medical / SynCardia to Participate in Voice of the Patient Event During AZ Tech Week</title>
<link>https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-to-participate-in-voice-of-the-patient-event-during-az-tech-week</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-to-participate-in-voice-of-the-patient-event-during-az-tech-week</guid>
<pubDate>Wed, 01 Apr 2026 12:00:00 GMT</pubDate>
<description>Arizona industry event will highlight patient experience, advanced heart failure care, and the real-world impact of life-sustaining therapiesTUCSON, Ariz., April 01, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC (“SynCardia”), maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will participate in the “Voice of the Patient” event during AZ Tech Week, a p</description>
</item>
<item>
<title>Philip Morris International Presents its Value Report 2025: change in motion</title>
<link>https://6ix.com/company/picard-medical-inc/news/philip-morris-international-presents-its-value-report-2025-change-in-motion-1</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/philip-morris-international-presents-its-value-report-2025-change-in-motion-1</guid>
<pubDate>Tue, 31 Mar 2026 08:30:00 GMT</pubDate>
<description>STAMFORD, CT, March 31, 2026--Philip Morris International (NYSE: PM) today released its Value Report 2025, offering a holistic perspective on the company’s approach to sustainable value creation. The report marks the completion of PMI’s 2025 Roadmap, communicating achievements for each aspiration introduced by the company in 2020, and introduces its Value Plan 2030+, set to guide the company’s continued path to sustainable growth.</description>
</item>
<item>
<title>Picard Medical Reports Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/picard-medical-inc/news/picard-medical-reports-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/picard-medical-reports-full-year-2025-financial-results</guid>
<pubDate>Wed, 25 Mar 2026 11:00:00 GMT</pubDate>
<description>Revenue Growth and Continued Adoption of SynCardia Total Artificial HeartTUCSON, Ariz., March 25, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today reported financial results for the year ended December 31, 2025. The year reflected a transformational period for the Company highlighted by revenue growth, improved operat</description>
</item>
<item>
<title>Perseverance Metals Issues Incentive Stock Options</title>
<link>https://6ix.com/company/picard-medical-inc/news/perseverance-metals-issues-incentive-stock-options-1</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/perseverance-metals-issues-incentive-stock-options-1</guid>
<pubDate>Tue, 24 Mar 2026 19:43:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - March 24, 2026) - Perseverance Metals Inc. (TSXV: PMI) ("Perseverance", "PMI" or the "Company") announces that it has issued incentive stock options (the "Options") under the Company's Long-Term Incentive Plan (the "Plan") to certain Officers, Directors, Advisors, employees, and consultants of the Company.An aggregate of 1,775,000 Options have been issued at an exercise price of $0.65 per share. All of the Options are subject to vesting over 36...</description>
</item>
<item>
<title>Perseverance Metals Closes $4.7M Second and Final Tranche of Private Placement for Total Gross Proceeds of $8.2M</title>
<link>https://6ix.com/company/picard-medical-inc/news/perseverance-metals-closes-dollar47m-second-and-final-tranche-of-private-placement-for-total-gross-proceeds-of-dollar82m-2</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/perseverance-metals-closes-dollar47m-second-and-final-tranche-of-private-placement-for-total-gross-proceeds-of-dollar82m-2</guid>
<pubDate>Mon, 23 Mar 2026 18:56:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - March 23, 2026) - Perseverance Metals Inc. (TSXV: PMI) ("Perseverance", "PMI" or the "Company") is pleased to announce that it has closed the second and final tranche of a non-brokered private placement (the "Second Tranche") for aggregate gross proceeds of $4,715,503. The Company previously announced (see PMI NR Mar 10 2026) a First Tranche closing of the Private Placement on March 10, 2026 for aggregate gross proceeds of $3,499,987. Together with.</description>
</item>
<item>
<title>Picard Medical / SynCardia to Present its Next-Generation Emperor Total Artificial Heart Technology at the American College of Cardiology’s Annual Scientific Session</title>
<link>https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-to-present-its-next-generation-emperor-total-artificial-heart-technology-at-the-american-college-of-cardiologys-annual-scientific-session</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-to-present-its-next-generation-emperor-total-artificial-heart-technology-at-the-american-college-of-cardiologys-annual-scientific-session</guid>
<pubDate>Fri, 20 Mar 2026 12:00:00 GMT</pubDate>
<description>Poster presentation and conference exhibit will feature early preclinical data on the Company’s fully implantable, autoregulating artificial heart platformTUCSON, Ariz., March 20, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will be presenting a poster consisting of new preclinical data related to its</description>
</item>
<item>
<title>Picard Medical / SynCardia Highlight Second Successful Total Artificial Heart Bridge to Transplant at UCSF Health</title>
<link>https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-highlight-second-successful-total-artificial-heart-bridge-to-transplant-at-ucsf-health</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-highlight-second-successful-total-artificial-heart-bridge-to-transplant-at-ucsf-health</guid>
<pubDate>Thu, 19 Mar 2026 12:00:00 GMT</pubDate>
<description>Case highlights young patient supported for 119 days with the SynCardia Total Artificial Heart before successful heart transplantationTUCSON, Ariz., March 19, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today highlighted a case reported by UCSF Health in which a patient in his twenties with advanced biventricular heart</description>
</item>
<item>
<title>Picard Medical / SynCardia Announce Successful Four-Year Bridge to Transplant with SynCardia Total Artificial Heart Support</title>
<link>https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-announce-successful-four-year-bridge-to-transplant-with-syncardia-total-artificial-heart-support</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-announce-successful-four-year-bridge-to-transplant-with-syncardia-total-artificial-heart-support</guid>
<pubDate>Tue, 17 Mar 2026 11:00:00 GMT</pubDate>
<description>29-year-old patient supported for more than 1,600 days on the SynCardia Total Artificial Heart before receiving a donor heart transplantTUCSON, Ariz., March 17, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that a 29-year-old patient successfully received a donor heart transplant after living for more tha</description>
</item>
<item>
<title>Picard Medical / SynCardia Highlight Total Artificial Heart on BTV Program Airing on FOX Business News</title>
<link>https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-highlight-total-artificial-heart-on-btv-program-airing-on-fox-business-news-32</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-highlight-total-artificial-heart-on-btv-program-airing-on-fox-business-news-32</guid>
<pubDate>Fri, 13 Mar 2026 10:00:00 GMT</pubDate>
<description>Segment showcases SynCardia Total Artificial Heart supporting patients with advanced heart failure and next-generation development programsTUCSON, Ariz., March 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that the SynCardia Total Artificial Heart (“STAH”) will be featured in an upcoming segment on BT</description>
</item>
<item>
<title>Picard Medical / SynCardia to Host Annual Business Update Featuring Key Opinion Leaders and Patient Testimonial</title>
<link>https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-to-host-annual-business-update-featuring-key-opinion-leaders-and-patient-testimonial-1</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-to-host-annual-business-update-featuring-key-opinion-leaders-and-patient-testimonial-1</guid>
<pubDate>Thu, 12 Mar 2026 20:05:00 GMT</pubDate>
<description>TUCSON, Ariz., March 12, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will host an its Annual Business Update virtual call, which will be webcasted, on Wednesday, March 25, 2026 at 4:30 p.m. EDT, following the filing of the Company’s Form 10-K for the fiscal year ended December 31, 2025. The webcast w</description>
</item>
<item>
<title>Picard Medical / SynCardia Showcases Leadership in Total Artificial Heart Therapy at Technology and Heart Failure Therapeutics Conference</title>
<link>https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-showcases-leadership-in-total-artificial-heart-therapy-at-technology-and-heart-failure-therapeutics-conference</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-showcases-leadership-in-total-artificial-heart-therapy-at-technology-and-heart-failure-therapeutics-conference</guid>
<pubDate>Mon, 02 Mar 2026 13:00:00 GMT</pubDate>
<description>New data highlight additional benefits beyond survival with the SynCardia Total Artificial Heart and preclinical progress for the next-generation Emperor systemTUCSON, Ariz., March 02, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Dr. Andre Simon, Vice President of Clinical Affairs, will</description>
</item>
<item>
<title>Picard Medical / SynCardia to Participate in Inaugural “Hands-On Training Day” at the Technology and Heart Failure Therapeutics Conference</title>
<link>https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-to-participate-in-inaugural-hands-on-training-day-at-the-technology-and-heart-failure-therapeutics-conference</link>
<guid isPermaLink="true">https://6ix.com/company/picard-medical-inc/news/picard-medical-syncardia-to-participate-in-inaugural-hands-on-training-day-at-the-technology-and-heart-failure-therapeutics-conference</guid>
<pubDate>Thu, 26 Feb 2026 13:00:00 GMT</pubDate>
<description>– Training will consist of an interactive clinical education program highlighting real world application of the SynCardia Total Artificial Heart in advanced heart failure patients –TUCSON, Ariz., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will participate in the inaugural “Hands</description>
</item>
</channel>
</rss>